Literature DB >> 117478

Noradrenergic agonists and antagonists: effects on conditioned fear as measured by the potentiated startle paradigm.

M Davis, D E Redmond, J M Baraban.   

Abstract

Clonidine (10-40 microgram/kg) produced a dose-dependent reduction of fear as measured by the potentiated startle effect (increased acoustic startle in the presence of a cue which had been previously paired with shock). The reduction of potential startle could not be accounted for entirely by a general depressant effect of clonidine on startle nor by an acceleration of extinction. Piperoxane and yohimbine, which are associated with anxiety in humans, increased potentiated startle, whereas propranolol and WB-4101 did not. These results provide further evidence that the potentiated startle paradigm in the rat is sensitive to drug that alter anxiety in humans. Moreover, they support the hypothesis that norepinephrine transmission is important for the expression of fear or anxiety.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 117478     DOI: 10.1007/bf00433036

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

1.  The alpha-adrenoceptor blocking effects of a new benzodioxane.

Authors:  D R Mottram; H Kapur
Journal:  J Pharm Pharmacol       Date:  1975-04       Impact factor: 3.765

2.  Iontophoresis of methionine-enkephalin in the locus coeruleus area.

Authors:  W S Young; S J Bird; M J Kuhar
Journal:  Brain Res       Date:  1977-07-01       Impact factor: 3.252

3.  Different alpha-adrenoreceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents.

Authors:  N E Andén; M Grabowska; U Strömbom
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

4.  Benzodiazepines: potentiation of a GABA inhibitory response in the dorsal raphe nucleus.

Authors:  D W Gallager
Journal:  Eur J Pharmacol       Date:  1978-05-15       Impact factor: 4.432

5.  Catecholamine receptors on locus coeruleus neurons: pharmacological characterization.

Authors:  J M Cedarbaum; G K Aghajanian
Journal:  Eur J Pharmacol       Date:  1977-08-15       Impact factor: 4.432

6.  The locus coeruleus noradrenergic system--evidence against a role in attention, habituation, anxiety and motor activity.

Authors:  T J Crow; J F Deakin; S E File; A Longden; S Wendlandt
Journal:  Brain Res       Date:  1978-10-27       Impact factor: 3.252

7.  Conditioned fear and startle magnitude: effects of different footshock or backshock intensities used in training.

Authors:  M Davis; D I Astrachan
Journal:  J Exp Psychol Anim Behav Process       Date:  1978-04

8.  Diazepam and flurazepam: effects on conditioned fear as measured with the potentiated startle paradigm.

Authors:  M Davis
Journal:  Psychopharmacology (Berl)       Date:  1979-03-29       Impact factor: 4.530

9.  The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyphenethyleneglycol (MHPG).

Authors:  J W Maas; S E Hattox; D H Landis; R H Roth
Journal:  Brain Res       Date:  1976-12-10       Impact factor: 3.252

10.  Effects of clonidine on habituation and sensitization of acoustic startle in normal, decerebrate and locus coeruleus lesioned rats.

Authors:  M Davis; J M Cedarbaum; G K Aghajanian; D S Gendelman
Journal:  Psychopharmacology (Berl)       Date:  1977-03-16       Impact factor: 4.530

View more
  63 in total

1.  Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans.

Authors:  Christian Grillon; Jeremy Cordova; Louise R Levine; Charles A Morgan
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

2.  Antagonism of lateral amygdala alpha1-adrenergic receptors facilitates fear conditioning and long-term potentiation.

Authors:  Stephanie C Lazzaro; Mian Hou; Catarina Cunha; Joseph E LeDoux; Christopher K Cain
Journal:  Learn Mem       Date:  2010-09-24       Impact factor: 2.460

3.  The effects of clonidine on the partial reinforcement extinction effect (PREE).

Authors:  G Halevy; J Feldon; I Weiner
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 4.  The neurocircuitry of addiction: an overview.

Authors:  M W Feltenstein; R E See
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

5.  Effect of yohimbine on reinstatement of operant responding in rats is dependent on cue contingency but not food reward history.

Authors:  Yu-Wei Chen; Kimberly A Fiscella; Samuel Z Bacharach; Gianluigi Tanda; Yavin Shaham; Donna J Calu
Journal:  Addict Biol       Date:  2014-07-27       Impact factor: 4.280

6.  The anxiogenic drug yohimbine reinstates palatable food seeking in a rat relapse model: a role of CRF1 receptors.

Authors:  Udi E Ghitza; Sarah M Gray; David H Epstein; Kenner C Rice; Yavin Shaham
Journal:  Neuropsychopharmacology       Date:  2005-12-07       Impact factor: 7.853

7.  Behavioral effects of phencyclidine on nicotine self-administration and reinstatement in the presence or absence of a visual stimulus in rats.

Authors:  Natashia Swalve; Steven T Pittenger; Rick A Bevins; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2015-04-07       Impact factor: 4.530

8.  Anxiolytics antagonize yohimbine's discriminative stimulus properties.

Authors:  R G Browne
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  A re-evaluation of the role of alpha 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat.

Authors:  W S Redfern; A Williams
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

10.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.